Risk Assessment and Treatment Progress of Extranodal NK/T-Cell Lymphoma
ENKTCL (extranodal NK/T-cell lymphoma) is a rare subtype of non-Hodgkin’s lymphoma. Its pathogenesis includes Epstein-Barr virus infection, ENKTCL-related gene abnormalities, abnormal activation of signal pathways, and change of tumor microenvironment. The disease develops rapidly with poor prognosis. Prognosis models include Ann Arbor staging model, IPI (international prognostic index) model, KPI (Korea prognostic index) model, PINK-E model and NRI (Nomogram risk index) model. Meanwhile, more and more independent prognostic factors of ENKTCL have been found in clinical research, which is of positive significance for risk assessment of ENKTCL. Current treatments include radiotherapy and chemotherapy, hematopoietic stem cell transplantation, and targeted therapy. This study reviews the pathogenesis, prognostic models, risk assessment and treatment progress of ENKTCL in order to improve its treatment effect.
CN
EN